-
Founded in:
1992-07-14 -
Country:
China -
Address:
Guilinyang Economic Development Zone, Meilan District, Haikou City -
Tax NO.:
91460000620000247L -
Registered Funds:
448.350021 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Famotidine |
This product is a histamine H2 receptor blocker. It has a significant inhibitory effect on gastric acid secretion, and can also inhibit the secretion of pepsin, and has a certain protective effect on animal experimental ulcers. It takes effect about 1 hour after taking the medicine, and the effect can last for more than 12 hours.
More
This product is a histamine H2 receptor blocker. It has a significant inhibitory effect on gastric acid secretion, and can also inhibit the secretion of pepsin, and has a certain protective effect on animal experimental ulcers. It takes effect about 1 hour after taking the medicine, and the effect can last for more than 12 hours. |
76824-35-6 | 69 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Omeprazole |
Proton pump inhibitor. This product is a fat-soluble weak alkaline drug that is easily concentrated in an acidic environment. After oral administration, it can be specifically distributed in the secretory tubules of the gastric mucosal parietal cells and converted into the active form of sulfenamide in this high-acid environment. Then, it irreversibly combines with the sulfhydryl group of the H, K-ATPase (also known as the proton pump) in the secretory membrane of the parietal cells through a disulfide bond to form a complex of sulfenamide and the proton pump, thereby inhibiting the activity of the enzyme and blocking the final step of gastric acid secretion. Therefore, this product has a strong and lasting inhibitory effect on gastric acid secretion caused by various reasons.
More
Proton pump inhibitor. This product is a fat-soluble weak alkaline drug that is easily concentrated in an acidic environment. After oral administration, it can be specifically distributed in the secretory tubules of the gastric mucosal parietal cells and converted into the active form of sulfenamide in this high-acid environment. Then, it irreversibly combines with the sulfhydryl group of the H, K-ATPase (also known as the proton pump) in the secretory membrane of the parietal cells through a disulfide bond to form a complex of sulfenamide and the proton pump, thereby inhibiting the activity of the enzyme and blocking the final step of gastric acid secretion. Therefore, this product has a strong and lasting inhibitory effect on gastric acid secretion caused by various reasons. |
73590-58-6 | 83 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Naproxen |
This product is a non-steroidal anti-inflammatory drug. Its analgesic, anti-inflammatory and antipyretic effects work by inhibiting the synthesis of prostaglandins.
More
This product is a non-steroidal anti-inflammatory drug. Its analgesic, anti-inflammatory and antipyretic effects work by inhibiting the synthesis of prostaglandins. |
0.1g | 22204-53-1 | 30 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Nicergoline |
This product is a semi-synthetic ergot alkaloid derivative. It has α receptor blocking and vasodilation effects. It can enhance the metabolism of brain cell energy and increase the utilization of oxygen and glucose. It can promote the conversion of neurotransmitter dopamine to enhance nerve conduction, strengthen brain protein biosynthesis, and improve brain function. Toxicity tests failed to show that nicergoline has teratogenic effects.
More
This product is a semi-synthetic ergot alkaloid derivative. It has α receptor blocking and vasodilation effects. It can enhance the metabolism of brain cell energy and increase the utilization of oxygen and glucose. It can promote the conversion of neurotransmitter dopamine to enhance nerve conduction, strengthen brain protein biosynthesis, and improve brain function. Toxicity tests failed to show that nicergoline has teratogenic effects. |
27848-84-6 | 35 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Aceglutamide |
After passing through the blood-brain-spinal fluid barrier, it is decomposed into glutamate and g-aminobutyric acid (GABA): glutamate is involved in information transmission in the central nervous system; g-aminobutyric acid can antagonize the excitotoxic effects of glutamate, improve nerve cell metabolism, maintain nerve stress resistance, reduce the effects of blood ammonia, and improve brain function.
More
After passing through the blood-brain-spinal fluid barrier, it is decomposed into glutamate and g-aminobutyric acid (GABA): glutamate is involved in information transmission in the central nervous system; g-aminobutyric acid can antagonize the excitotoxic effects of glutamate, improve nerve cell metabolism, maintain nerve stress resistance, reduce the effects of blood ammonia, and improve brain function. |
2490-97-3 | 6 |